Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HTR6 | P50406 | 2/20 | 0.54 |
| ▸ | MPO | P05164 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 5/20 | 0.52 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | CA12 | O43570 | 4/20 | 0.52 |
| ▸ | CA9 | Q16790 | 4/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | AGO2 | Q9UKV8 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10060475 | 0.87 | ALDH1A1 (0.40) | CA2CA1CA12CA9CA14 | |
| SCHEMBL8951866 | 0.82 | TSHR (0.50) | TSHRLMNAHTR6MPOCYP3A4 | |
| SCHEMBL7758469 | 0.82 | TSHR (0.52) | TSHRLMNAHTR6MPOCYP3A4 | |
| SCHEMBL105259 | 0.81 | ALDH1A1 (0.50) | LMNACA2CA1CA12CA9 | |
| SCHEMBL10060466 | 0.80 | CA12 (0.46) | LMNACA2CA1CA12CA9 | |
| SCHEMBL2657775 | 0.78 | ALDH1A1 (0.36) | CA2CA1CA12CA9CA14 | |
| SCHEMBL178444 | 0.78 | GAA (0.56) | TSHRLMNACYP3A4CYP2C9CA2 | |
| SCHEMBL14520771 | 0.78 | ENPP2 (0.52) | — | |
| SCHEMBL17315251 | 0.77 | CA2 (0.60) | TSHRHTR6CA2CA1CA12 | |
| SCHEMBL17373703 | 0.77 | TSHR (0.45) | TSHRLMNAHTR6MPOCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 468 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468231-B2 | Imaging members | XEROX CORPORATION (US) | 2008-12-23 | — | — | US | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| US-20060177751-A1 | Imaging members | XEROX CORPORATION | 2006-08-10 | — | — | US | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-20240270699-A1 | COMPOUNDS HAVING N-ARYLPYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC AGENTS | LOMOND THERAPEUTICS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-11760775-B2 | Steroids and protein-conjugates thereof | REGENERON PHARMACEUTICALS, INC. | 2023-09-19 | — | — | US | disclosed |
| US-11760775-B2 | Steroids and protein-conjugates thereof | REGENERON PHARMACEUTICALS, INC. | 2023-09-19 | — | — | US | disclosed |
| US-11673870-B2 | Pharmaceutical compounds | SAREUM LIMITED (GB) | 2023-06-13 | — | — | US | disclosed |
| US-11673870-B2 | Pharmaceutical compounds | SAREUM LIMITED (GB) | 2023-06-13 | — | — | US | disclosed |
| WO-2023043630-A1 | COMPOUNDS HAVING N-ARYLPYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC AGENTS | LOMOND THERAPEUTICS, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| US-20210087154-A1 | PHARMACEUTICAL COMPOUNDS | SAREUM LIMITED (GB) | 2021-03-25 | — | — | US | disclosed |
| EP-0289216-A2 | Electrophotographic imaging member | XEROX CORPORATION (US) | 1988-11-02 | — | — | EP | disclosed |
| US-4780385-A | GREATER RESISTANCE TO FORMATION OF CHARGE DEFICIENT SPOTS | XEROX CORPORATION (US) | 1988-10-25 | — | — | US | disclosed |
| EP-0149914-B1 | OVERCOATED ELECTROPHOTOGRAPHIC IMAGING MEMBER | XEROX CORPORATION (US) | 1988-08-10 | — | — | EP | disclosed |
| US-4588667-A | Electrophotographic imaging member and process comprising sputtering titanium on substrate | XEROX CORPORATION (US) | 1986-05-13 | — | — | US | disclosed |
| EP-0161933-A2 | Electrophotographic imaging | XEROX CORPORATION (US) | 1985-11-21 | — | — | EP | disclosed |
| EP-0149914-A1 | Overcoated electrophotographic imaging member | XEROX CORPORATION (US) | 1985-07-31 | — | — | EP | disclosed |
| US-4515882-A | CHARGE TRANSFER COMPOUNDS AND CHARGE INJECTION ENABLING PARTICLES | XEROX CORPORATION (US) | 1985-05-07 | — | — | US | disclosed |
| US-4303673-A | N-Propionylsarcosineanilides, process for their preparation, and pharmaceutical compositions containing them | A. NATTERMANN & CIE. GMBH (DE) | 1981-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270699-A1 | COMPOUNDS HAVING N-ARYLPYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC AGENTS | IRAK3, IRAK1, IRAK2 | TSHR 2092/4885LMNA 3635/4885HTR6 1141/4885 |
| US-11673870-B2 | Pharmaceutical compounds | TYK2, JAK2, SGK2 | TSHR 1644/4885LMNA 3390/4885HTR6 1642/4885 |
| US-20210087154-A1 | PHARMACEUTICAL COMPOUNDS | TYK2, JAK2, SGK2 | TSHR 1644/4885LMNA 3390/4885HTR6 1642/4885 |
| US-11760775-B2 | Steroids and protein-conjugates thereof | SERPINA6, NR3C1, NR3C2 | TSHR 809/4885LMNA 3616/4885HTR6 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.